EN | RU
EN | RU

Help Support

Back

Selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient with a good response rate

Selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient with a good response rate Selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient with a good response rate
Selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient with a good response rate Selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient with a good response rate

What's new?

For treating middle-aged females with advanced PFCW (patellofemoral cartilage wear), clinicians may use APS (autologous protein solution) injection as it demonstrates a 54% response rate.

In a study, it was found out that in middle-aged females with advanced PFCW, there is a 54% response rate at 1-year follow-up to a single or second APS injection. Moderate temporary fares are likely to occur without impacting the clinical outcomes.


This prospective, single-centre, single-arm study aimed to investigate the benefit, durability, and safety of APS injections for unilateral PFOA (patellofemoral osteoarthritis)-related knee pain. From April 2016 to May 2017, all female patients suffering predominantly from symptomatic PFOA were enrolled.


A total of 50 moderate-severe (86%) PFCW females were treated with a unilateral intra-articular APS injection. The KOOS (Knee Injury and Osteoarthritis Outcome Score), NRS (Numeric Rating Scales), Kujala, UCLA, and EQ-5D (European Quality of Life 5 Dimensions) were assessed at baseline and 1, 3, 6, and 12 months post-injection.


Based on KOOS pain improvement >10 points, TRR (Therapeutic response rate) was assessed. Absolute improvement for both therapy responders and non-responders was evaluated. The second APS injection was given if the patient demonstrated unsatisfactory improvement after 3 months.


The overall number of APS responders was found to remain stable over the study period with 53.7% at the final follow-up. After 1 year, APS responders demonstrated improvement with 30.5±11.4 points on KOOS pain. On the other hand, non-responders deteriorated with −5.9±8.9 points relative to baseline as depicted in Figure 1.


Figure 1: Absolute KOOS pain change for APS responders and non-responders. Treatment responders were defined as KOOS pain improvement >10 points relative to baseline (Mean+SD).


Overall, the enrolled subjects improved from 40.3±18.7 to 57.3±24.8 points on KOOS pain. NRS improved from 6.7±2.2 to 4.5±2.9 and the Kujala score improved from 48.4 ± 13.0 to 56.3 ± 18.1 at 12 months. The UCLA activity and the EQ-5D VAS scores illustrated no statistically significant difference at any post-injection follow-up point as shown in Table 1:

A remarkable improvement was witnessed for the other KOOS subscales at each follow-up when compared to baseline with a consistent early improvement 1-month post-injection. In 28 subjects, the second APS injection was given that illustrated low efficacy in initially poor responding patients after 3 months.

Definite synovitis patients improved more on KOOS symptoms and KOOS ADL (activities of daily living) at 12 months in comparison with non-synovitis patients. Effusion (29%) and transient arthralgia (46%) were commonly observed during the first month after injection. Thus, APS can be used as a selective treatment for advanced PFOA in middle-aged female patients.

Source:

Knee Surgery, Sports Traumatology, Arthroscopy

Article:

Autologous protein solution as selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient: 54% response rate at1 year follow-up

Authors:

Wouter Van Genechten et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: